Friday, May 14, 2021

Re: [IAC#RG] New DRDO Drug 2-DG is based on Acharya Balkrishna’s research

I too searched literature on 2-DG and found this pre-print (meaning not peer-reviewed) publication from Patanjali on Researchgate website. It is a theoretical study based on computer simulation. One of the co-authors is an ex-Director of a DRDO-Institute. 

2-DG is a long-known molecule, having been developed as an anti-cancer metabolite. The present group has boldly tested it in Covid-19 patients and have shown favourable results and have obtained DCGI-approval. To that extent the work done is novel. It remains to be seen how it works out in field use. The side effects 

Incidentally, DRDO-INMAS has published papers using this molecule more than a decade ago as an adjuvant in radiation therapy for a few cancers. 

However, some experts have expressed reservations against 2-DG for treating covid-19 patients as expressed in The Hindu. 

There is a Swedish company that announced on March 11th, a nasal spray containing 2-DG.

Dr. Rajan

From: indiaresists-request@lists.riseup.net <indiaresists-request@lists.riseup.net> on behalf of Pankaj Jangid <pankaj@codeisgreat.org>
Sent: Friday, May 14, 2021 10:25 AM
To: indiaresists@lists.riseup.net <indiaresists@lists.riseup.net>
Subject: [IAC#RG] New DRDO Drug 2-DG is based on Acharya Balkrishna's research
 
I started to dig about this new drug 2-DG, which was launched last week
by DRDO and Dr. Reddy's. This drug is claimed to reduce the oxygen
demand by a body infected with covid-19.

Reading more on this, I found that this is actually based on a research
paper by Acharya Balkrishna et al. of Patanjali Ayurveda. Here is the
original paper published on the aggregator ResearchGate:

https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.researchgate.net%2Fpublication%2F340332773_Glucose_antimetabolite_2-Deoxy-D-Glucose_and_its_derivative_as_promising_candidates_for_tackling_COVID-19_Insights_derived_from_in_silico_docking_and_molecular_simulations&amp;data=04%7C01%7C%7Caac01eb4e3cf44a4a7fc08d916bb719d%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637565816615923917%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=a8ahOYlOxOBv6QoAL4ICihR09l%2Fa2tDD%2FMf82uU95SE%3D&amp;reserved=0

--
Regards,
Pankaj Jangid

No comments:

Post a Comment